Imunon, Inc. (IMNN) 是一家上市公司 属于 医疗保健 板块，经营于 生物科技 行业. 公司总部位于 Lawrenceville, NJ, 美国. 现任CEO为 Michael H. Tardugno.
IMNN 拥有 IPO日期为 1999-03-01, 25 名全职员工, 在 NASDAQ Capital Marke, 市值为 $7.94M.
Imunon, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. The company was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. Imunon, Inc. was founded in 1982 and is based in Lawrenceville, New Jersey.
